Skip to content
News & Publications
News
Publications
Contact Us
About Us
History
Patents
Technology
Signaling Chain HOmoOLigomerization (“SCHOOL”) Platform Basics
Macrophage Modulation
Macrophage Imaging
Pipeline
Therapeutic Areas
Cancer
Autoimmune Diseases
Retinopathy
Atherosclerosis
Sepsis/ARDS & COVID
Other Inflammatory Diseases
Partners & Collaborators
Menu
Understanding Nature. Improving Life
Type and press enter to search
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma
SignaBlok
>
News
>
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma
SignaBlok
>
News
>
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma
SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma
Post navigation
Previous Post
SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis
Next Post
SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.
Vera
View posts by Vera
Scroll to top
close ×
